Chile Healthcare Technology & Digital Integration
Chile is actively cementing its position as a regional leader in digital health and artificial intelligence integration, sectors that align with Trump Administration priorities. Driven by the demands of an aging population and a high burden of chronic illness, the Chilean government and private health networks are directing substantial efforts toward modernizing health systems as outlined by Chile’s National Digital Health Strategy (Estrategia Nacional de Salud Digital).
At the forefront of Chile’s medical technology transition is PRISMA IA 2.0, an ongoing five-year initiative launched in December 2025. The program works to validate and scale collaborative AI tools to manage clinical data and deploy predictive healthcare. It is supported by a $2.8 million grant from the Chilean Economic Development Agency (CORFO). Additionally, CORFO has invested $3 million into automated triage coordination software to reduce public hospital waiting lists.
Furthermore, the Ministry of Health has established new compliance frameworks, such as the Norma General Técnica N° 237, which mandates strict interoperability and cybersecurity standards for all telemedicine platforms used in Chile. Cybersecurity and data protection are top priorities in all sectors that use technological tools. To support Chile’s new medical software systems, there may be opportunities in cybersecurity and health IT systems to address effectiveness and safety across Chilean medical networks.
As Chile’s medical networks modernize, telemedicine and remote monitoring technologies are in high demand. Opportunities may exist in software-as-a-service (SaaS) platforms to provide wider access to telemedicine. Wearable devices that manage chronic disease outpatients or other monitoring needs may also provide an opportunity. Chile’s focus on integrating AI nationwide extends to the country’s medical sector. High demand exists for AI-enabled tools like diagnostic imaging and triage algorithms capable of processing high-volume clinical data. Including access to Spanish-language interfaces and training courses is critical to companies exporting AI tools to the Chilean market.
To effectively enter the Chilean market, U.S. exporters must understand its highly segmented, two-tier healthcare system. The Fondo Nacional de Salud (FONASA), Chile’s public healthcare system, gives access to all public hospitals and registered private clinics and is used by approximately 76–79% of the population. While private insurance companies (ISAPREs) cover 16–19% of the population (predominantly higher-income earners). ISAPREs operate their own premium clinical networks that look for innovative products with high service standards.
Moreover, entering the Chilean market requires cooperation with an evolving regulatory landscape. Currently, Chile’s Institute of Public Health (ISP) only mandates official registration for a narrow scope of basic medical supplies like surgical gloves and needles. However, U.S. manufacturers are strongly advised to undergo voluntary ISP registration. Presenting U.S. FDA approval or ISO certification establishes crucial market trust and prepares companies for pending legislation like la Ley de Fármacos II, which aims to mandate registration for all medical devices. In addition to the Norma General Técnica N° 237, for software and IT vendors, digital health platforms need official certification from Chile’s National Center for Health Information Systems (CENS).
There is a promising market for export in telemedicine, AI-based tracking systems, and healthcare IT in Chile. due to the U.S.’s technological reputation, companies and products may be well positioned to modernize Chile’s health systems and medical networks. Export-Import (EXIM) Bank of the United States may be able to provide financing solutions for products that meet minimum U.S. content requirements.
Companies may also consider attending or exhibiting at the annual ExpoSalud trade show in November in Santiago.
Contact The U.S. Commercial Service in Chile to discuss whether there is opportunity for your products in the healthcare sector